CA1336506C - Methode de protection contre les effets chimiotherapeutiques - Google Patents

Methode de protection contre les effets chimiotherapeutiques

Info

Publication number: CA1336506C
Authority: CA; Canada
Prior art keywords: aminopropylamino; derivative; ethyl dihydrogen; dihydrogen phosphorothioate; mitomycin
Prior art date: 1988-02-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000591907A

Other languages

English (en)

Inventor

Philip S. Schein

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

MedImmune LLC

Original Assignee

MedImmune LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-23

Filing date

1989-02-23

Publication date

1995-08-01

1989-02-23 Application filed by MedImmune LLC filed Critical MedImmune LLC

1995-08-01 Application granted granted Critical

1995-08-01 Publication of CA1336506C publication Critical patent/CA1336506C/fr

2012-08-01 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000000694 effects Effects 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title description 3
230000000973 chemotherapeutic effect Effects 0.000 title 1
JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims abstract description 17
238000002512 chemotherapy Methods 0.000 claims abstract description 6
210000001185 bone marrow Anatomy 0.000 claims abstract description 4
231100000331 toxic Toxicity 0.000 claims abstract description 4
230000002588 toxic effect Effects 0.000 claims abstract description 4
231100000457 cardiotoxic Toxicity 0.000 claims abstract description 3
230000001451 cardiotoxic effect Effects 0.000 claims abstract description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 14
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
229960004857 mitomycin Drugs 0.000 claims description 11
229930192392 Mitomycin Natural products 0.000 claims description 10
238000001990 intravenous administration Methods 0.000 claims description 7
229960004562 carboplatin Drugs 0.000 claims description 6
229960004679 doxorubicin Drugs 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 claims description 3
HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 claims description 3
UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 claims description 2
HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 claims description 2
HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 claims description 2
UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 claims description 2
190000008236 carboplatin Chemical compound 0.000 claims 2
239000002246 antineoplastic agent Substances 0.000 abstract description 10
229940127089 cytotoxic agent Drugs 0.000 abstract description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
239000000243 solution Substances 0.000 description 12
OJZGWRZUOHSWMB-UHFFFAOYSA-N ethoxy-dihydroxy-sulfanylidene-$l^{5}-phosphane Chemical compound CCOP(O)(O)=S OJZGWRZUOHSWMB-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
206010051779 Bone marrow toxicity Diseases 0.000 description 6
231100000366 bone marrow toxicity Toxicity 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 4
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
206010048610 Cardiotoxicity Diseases 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
231100000259 cardiotoxicity Toxicity 0.000 description 3
230000007681 cardiovascular toxicity Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000011282 treatment Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
QJWQDMBGXNKPAS-UHFFFAOYSA-N 3-azaniumylpropyl(2-bromoethyl)azanium;dibromide Chemical compound Br.Br.NCCCNCCBr QJWQDMBGXNKPAS-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000008156 Ringer's lactate solution Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
-1 alkali metal salts Chemical class 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000008366 buffered solution Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
GHKSKVKCKMGRDU-UHFFFAOYSA-N 2-(3-aminopropylamino)ethanol Chemical compound NCCCNCCO GHKSKVKCKMGRDU-UHFFFAOYSA-N 0.000 description 1
CWHOHHKTRJUFTR-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;hydrate Chemical compound O.NCCCNCCSP(O)(O)=O CWHOHHKTRJUFTR-UHFFFAOYSA-N 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229950004406 porfiromycin Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RIFYBBXGYKFBFC-UHFFFAOYSA-K trisodium;thiophosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=S RIFYBBXGYKFBFC-UHFFFAOYSA-K 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CA000591907A 1988-02-23 1989-02-23 Methode de protection contre les effets chimiotherapeutiques Expired - Lifetime CA1336506C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15910488A	1988-02-23	1988-02-23
US159,104		1988-02-23

Publications (1)

Publication Number	Publication Date
CA1336506C true CA1336506C (fr)	1995-08-01

Family

ID=22571099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000591907A Expired - Lifetime CA1336506C (fr)	1988-02-23	1989-02-23	Methode de protection contre les effets chimiotherapeutiques

Country Status (5)

Country	Link
EP (1)	EP0409845A4 (fr)
JP (1)	JPH03503888A (fr)
AU (1)	AU636107B2 (fr)
CA (1)	CA1336506C (fr)
WO (1)	WO1989007942A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2450791C1 (ru) *	2010-10-18	2012-05-20	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи"	Способ определения кардиотоксических осложнений у больных хроническим лимфолейкозом
CN104230984A (zh) *	2013-06-08	2014-12-24	上海医药工业研究院	一种三水合3-氨基丙基胺乙基硫代磷酸的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3827974A1 (de) *	1988-08-18	1990-02-22	Boehringer Mannheim Gmbh	Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
US5567686A (en) *	1992-03-13	1996-10-22	Arch Development Corporation	Method for protection against genotoxic mutagenesis
US6573253B2 (en)	1997-02-12	2003-06-03	Medimmune Oncology Inc.	Methods for the administration of amifostine and related compounds
US6051563A (en) *	1997-02-12	2000-04-18	U.S. Bioscience, Inc.	Methods for the administration of amifostine and related compounds
US6239119B1 (en)	1998-04-27	2001-05-29	Medimmune Oncology, Inc.	Topical administration of amifostine and related compounds
US6489312B1 (en)	1999-06-15	2002-12-03	Medimmune Oncology, Inc.	Pharmaceutical formulations comprising aminoalkyl phosphorothioates
US7053072B2 (en)	2001-05-11	2006-05-30	Medimmune Oncology, Inc.	Methods for the administration of amifostine and related compounds
CN102260288B (zh) *	2010-06-08	2014-02-26	成都大有得药业有限公司	一种三水合3-氨基丙基胺乙基硫代磷酸的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4656034A (en) *	1985-05-20	1987-04-07	Survival Technology, Inc.	Absorption enhancing agents

1989
- 1989-02-21 EP EP19890902904 patent/EP0409845A4/en not_active Withdrawn
- 1989-02-21 AU AU31940/89A patent/AU636107B2/en not_active Expired
- 1989-02-21 WO PCT/US1989/000624 patent/WO1989007942A1/fr not_active Ceased
- 1989-02-21 JP JP1502696A patent/JPH03503888A/ja active Pending
- 1989-02-23 CA CA000591907A patent/CA1336506C/fr not_active Expired - Lifetime

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2450791C1 (ru) *	2010-10-18	2012-05-20	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи"	Способ определения кардиотоксических осложнений у больных хроническим лимфолейкозом
CN104230984A (zh) *	2013-06-08	2014-12-24	上海医药工业研究院	一种三水合3-氨基丙基胺乙基硫代磷酸的制备方法
CN104230984B (zh) *	2013-06-08	2017-02-08	国药集团国瑞药业有限公司	一种三水合3‑氨基丙基胺乙基硫代磷酸的制备方法

Also Published As

Publication number	Publication date
EP0409845A1 (fr)	1991-01-30
JPH03503888A (ja)	1991-08-29
WO1989007942A1 (fr)	1989-09-08
AU636107B2 (en)	1993-04-22
AU3194089A (en)	1989-09-22
EP0409845A4 (en)	1991-07-03

Legal Events

Date	Code	Title	Description
2012-08-01	MKEX	Expiry

Publication	Publication Date	Title
SU1349700A3 (ru)	1987-10-30	Способ получени (2-оксо-1,2,3,5-тетрагидроимидазо-/2,1- @ /хиназолинил)оксиалкиламидов,их оптических изомеров или фармакологически приемлемых солей с кислотами
KR0142907B1 (ko)	1998-07-15	골수억제제
IL93556A (en)	1996-10-16	Pharmaceutical compositions comprising stabilized nitric oxide-primary amine complexes useful as cardiovascular agents
CA1336506C (fr)	1995-08-01	Methode de protection contre les effets chimiotherapeutiques
JPS6259715B2 (fr)	1987-12-12
US4066650A (en)	1978-01-03	Keto-aldehyde-amine addition products and method of making same
KR101838764B1 (ko)	2018-03-14	(ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
US5804571A (en)	1998-09-08	Method for protection from AZT side effects and toxicity
JP2919867B2 (ja)	1999-07-19	抗腫瘍剤
CA1078736A (fr)	1980-06-03	Usages therapeutiques du 4-carbamoyl-5-hydroxyimidazole
EP0373663B1 (fr)	1993-10-27	Les esters de castanospermine pour l'inhibition de la métastase de tumeurs
RU2353623C1 (ru)	2009-04-27	Корректор цитостатической полихимиотерапии
EP0416286A1 (fr)	1991-03-13	Sylfonylhydrazines et leur application comme agents antinéoplastiques et comme agents pour la lutte contre les trypanosomes
WO2005085188A2 (fr)	2005-09-15	Composes et procedes pour la therapie antitumorale
AU2003298077A1 (en)	2005-07-05	Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
CA1069125A (fr)	1980-01-01	La 4-imino-1,3-diazabicyclo-(3.1.0) hexan-2-one
US4673690A (en)	1987-06-16	Acylated enamides and pharmaceutical compositions containing them
JP2000302762A (ja)	2000-10-31	放射線および化学療法における感受性増強剤であるグリシジアゾール金属塩、並びにそれらの製造方法および使用
Sugiura	1967	Effect of 1, 3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) and two related compounds on a spectrum of tumors
US8877734B2 (en)	2014-11-04	Seleny-methyluracil compounds, radiosensitizer and pharmaceutical composition using them
US5621003A (en)	1997-04-15	Maillard reaction inhibitor
FI90982B (fi)	1994-01-14	Analogiamenetelmä terapeuttisesti käyttökelpoisten mitomysiinifosfaattijohdannaisten valmistamiseksi
US3169091A (en)	1965-02-09	Process for inhibiting tumors with substituted pyrazoles
EP0432630B1 (fr)	1994-03-16	Agent antitumoral
US4423076A (en)	1983-12-27	1-Branched-alkyl-3-(2-haloethyl)-3-nitrosoureas as novel antitumor agents